NeuroTrauma Sciences
Manufacturing · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2655 Northwinds Pkwy Ste 5C, Alpharetta,...Phone Number
(833) 278-2888Website
www.neurotraumasciences.comRevenue
<$5 MillionIndustry
About NeuroTrauma Sciences
NeuroTrauma Sciences (NTS) is a clinical stage biopharmaceutical company established in 2016, dedicated to enhancing the treatment of stroke patients, specifically focusing on acute ischemic stroke and chronic stroke. The company is currently advancing its lead compound, NTS-104, through Phase 1 clinical trials, expected to complete in 2025. NTS is led by a team of experienced professionals in neuroscience and drug development, aiming to innovate in the field of neuroprotection. Their target clients include healthcare providers and patients affected by stroke, as well as potential partners in the pharmaceutical industry.Explore more
NeuroTrauma Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to NeuroTrauma Sciences
Compare insights from companies similar to NeuroTrauma Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NeuroTrauma Sciences Tech Stack
A closer look at the technologies used by NeuroTrauma Sciences
See more technologies
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeuroTrauma Sciences
Sign Up For FreeTo access detailed company insights
NeuroTrauma Sciences (NTS) is a clinical stage biopharmaceutical company established in 2016, dedicated to enhancing the treatment of stroke patients, specifically focusing on acute ischemic stroke and chronic stroke. The company is currently advancing its lead compound, NTS-104, through Phase 1 clinical trials, expected to complete in 2025. NTS is... Read More
